ARCHIVES

NCI Planning To Switch Drug Development Emphasis From Compound To Human Cancer Oriented Strategy

This article is from The Cancer Letter archive.

Vol. 10 No. 41 | October 26, 1984

Download PDF Visit The Full Archive

Related Articles

NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study.

June 3, 2005

An Unusual Week Of Deals In Oncology: Alliances, Sales, and Dramatic Moves

November 13, 1998

Professional Societies: Organizations Form Alliance To Call For Quality Cancer Care

October 9, 1998

Letter In Response To Hadley; RFA Available

July 7, 1995

In Brief: Bernard Fisher Professorship Endowed By ICI Pharma; Brady wins RSNA Medal

January 12, 1990

Studies of Oncotype DX Test Presented at ASCO Symposium

January 31, 2014